Literature DB >> 2747655

Transcriptional regulation and chromosomal assignment of the mammalian calbindin-D28k gene.

S Varghese1, L L Deaven, Y C Huang, R K Gill, A M Iacopino, S Christakos.   

Abstract

To determine whether 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3] regulates transcription of the rat renal calbindin-D28k gene, the rate of calbindin-D28k mRNA synthesis was measured directly in nuclei using the in vitro nuclear transcription assay. Nuclei were prepared from kidneys of vitamin D-deficient rats at various times after a single ip injection of 1,25-(OH)2D3, and transcription was allowed to proceed in vitro in the presence of [32P]UTP for 30 min at 29 C, at which time the incorporation of UTP into trichloroacetic acid-precipitable material was optimal. Incorporation of UTP was decreased by 64.6% by alpha-amanitin, which selectively inhibits polymerase II. Purified [32P]RNA was analyzed for newly synthesized calbindin-D-28k gene transcripts by hybridization to calbindin-D28k cDNA immobilized on nitrocellulose filters. Using this assay we found that the first significant increase in calbindin-D28k gene transcription occurred at 1 h, and the peak of transcriptional activity occurred at 2 h. Within 12 h of 1,25-(OH)2D3 treatment, calbindin-D28k gene transcription returned to control levels. Using Northern blot analysis, a significant increase in calbindin-D RNA was first observed 2 h after hormone administration, reaching a maximum at 12 h. Renal calbindin-D28k protein levels are significantly increased by 3 h and reach a maximum value 48 h after hormone administration. Our results suggest that the early increase in renal calbindin-D28k may be due to transcriptional regulation. The long time lag between transcription and the peak of calbindin mRNA and calbindin protein accumulation may reflect the involvement of post-transcriptional mechanisms.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2747655     DOI: 10.1210/mend-3-3-495

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  7 in total

1.  Intracellular calcium ion response to glucose in beta-cells of calbindin-D28k nullmutant mice and in betaHC13 cells overexpressing calbindin-D28k.

Authors:  Jai Parkash; Muhammad A Chaudhry; Ayman S Amer; Sylvia Christakos; William B Rhoten
Journal:  Endocrine       Date:  2002-08       Impact factor: 3.633

2.  Box I and II motif from myelin basic protein gene promoter binds to nuclear proteins from rodent brain.

Authors:  K S Kimbro; P A Rosenberg; R A Saavedra
Journal:  J Mol Neurosci       Date:  1994       Impact factor: 3.444

3.  Regulation of renal calbindin expression during cisplatin-induced kidney injury.

Authors:  Blessy George; John T Szilagyi; Melanie S Joy; Lauren M Aleksunes
Journal:  J Biochem Mol Toxicol       Date:  2022-04-10       Impact factor: 3.568

4.  Identification of sequence elements in mouse calbindin-D28k gene that confer 1,25-dihydroxyvitamin D3- and butyrate-inducible responses.

Authors:  R K Gill; S Christakos
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

5.  Vitamin D and adaptation to dietary calcium and phosphate deficiencies increase intestinal plasma membrane calcium pump gene expression.

Authors:  Q Cai; J S Chandler; R H Wasserman; R Kumar; J T Penniston
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-15       Impact factor: 11.205

6.  Influence of feeding and UVB exposition on the absorption mechanisms of calcium in the gastrointestinal tract of veiled chameleons (Chamaeleo calyptratus).

Authors:  D Haxhiu; S Hoby; C Wenker; A Boos; M P Kowalewski; F Lewis; A Liesegang
Journal:  J Anim Physiol Anim Nutr (Berl)       Date:  2014-05-22       Impact factor: 2.130

7.  AF4 and AF4-MLL mediate transcriptional elongation of 5-lipoxygenase mRNA by 1, 25-dihydroxyvitamin D3.

Authors:  Khalil Ahmad; Bastian Scholz; Ricardo Capelo; Ilona Schweighöfer; Astrid Stefanie Kahnt; Rolf Marschalek; Dieter Steinhilber
Journal:  Oncotarget       Date:  2015-09-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.